Momentus Inc. (MNTS): Nasdaq/NYSE listing notice — Momentus receives Nasdaq deficiency notice for bid price below $1.00

Momentus Inc.

Nasdaq notified Momentus (MNTS) on March 27, 2024, of non-compliance with minimum bid price rule.
Company has 180 calendar days, until September 23, 2024, to regain compliance.
If closing bid price closes at $1.00+ for 10 consecutive business days, Nasdaq will confirm compliance.
Failure to cure may lead to delisting; company may seek a second 180-day period or appeal to Nasdaq panel.
Momentus intends to monitor bid price and evaluate options, including a potential reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Momentus Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 27, 2024, Momentus Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Capital Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock, par value $0.00001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate impact on th

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Momentus Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-016594

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.